Pacira BioSciences Inc (PCRX)
30.33
-0.13
(-0.43%)
USD |
NASDAQ |
May 31, 16:00
30.37
+0.04
(+0.13%)
After-Hours: 20:00
Pacira BioSciences Research and Development Expense (Annual): 76.26M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 76.26M |
| December 31, 2022 | 84.80M |
| December 31, 2021 | 55.54M |
| December 31, 2020 | 59.42M |
| December 31, 2019 | 72.12M |
| December 31, 2018 | 55.69M |
| December 31, 2017 | 57.29M |
| December 31, 2016 | 45.68M |
| Date | Value |
|---|---|
| December 31, 2015 | 28.66M |
| December 31, 2014 | 18.73M |
| December 31, 2013 | 21.56M |
| December 31, 2012 | 9.937M |
| December 31, 2011 | 14.87M |
| December 31, 2010 | 18.63M |
| December 31, 2009 | 26.23M |
| December 31, 2008 | 33.21M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
55.54M
Minimum
2021
84.80M
Maximum
2022
69.63M
Average
72.12M
Median
2019
Research and Development Expense (Annual) Benchmarks
| Dynavax Technologies Corp | 54.89M |
| SIGA Technologies Inc | -- |
| Ligand Pharmaceuticals Inc | 24.54M |
| Supernus Pharmaceuticals Inc | 91.59M |
| FibroGen Inc | 282.86M |